10.1001/archinte.166.9.1003 146 RazayG.VreugdenhilA.WilcockG
There are some concerns around use of the GLP-1 agents, such as weight regain after stopping treatment, the potential for a loss of skeletal muscle mass, long-term adherence, and the limited evidence that exists for long-term safety, Moiz et al say
3 Aqu la explicacin de su peligro: Ciertas bacterias del intestino metabolizan la L-carnitina que no es utilizada por el cuerpo, es decir la excedente, y generan un desecho llamado TMAO (xido de trimethylamina) Qu tiene de malo la TMAO
Clinical Nutrition ESPEN , 37, pp.923
The medication works by altering food preferences and reward pathways in the brain to help combat obesity and insulin resistance
[90] [91] It is the most abundant amino acid in the apoplast of tomatoes